Biotech News
Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026
Among patients previously on long-term prophylaxis (LTP) in HAELO Phase 3 trial, monthly attack rate decreased by 81% following lonvo-z dosing compared with prior LTP 100% of patients receiving 50 mg of lonvo-z across Phase 1/2 clinical trial and HAELO were LTP-free as of the data cutoffs Among 23
